tofacitinib sold brand xeljanz among others medication used treat rheumatoid arthritis psoriatic arthritis ankylosing spondylitis polyarticular course juvenile idiopathic arthritis ulcerative janus kinase jak discovered developed national institutes health pfizer common side effects include diarrhea headache high blood serious side effects may include infections cancer pulmonary safety committee european medicines agency began review tofacitinib recommended doctors temporarily prescribe mg twicedaily dose people high risk pulmonary us food drug administration fda also released warnings risk blood important side effect jakinibs serious bacterial mycobacterial fungal viral infections phase iii trials tofacitinib among opportunistic infections pulmonary tuberculosis tb reported cases initially negative upon screening approved medical use united states november extended release version approved february available generic tofacitinib citrate approved medical use united states indication treat adults moderately severely active rheumatoid arthritis inadequate response intolerant european union combination methotrexate tofacitinib citrate indicated treatment moderate severe active rheumatoid arthritis ra adults responded inadequately intolerant one diseasemodifying antirheumatic given monotherapy case intolerance methotrexate treatment mtx may fda approved tofacitinib citrate treatment adult patients us moderately severely active ulcerative tofacitinib citrate first oral jak inhibitor approved use chronic ulcerative colitis tofacitinib initially approved european regulatory agencies concerns efficacy although european commission approved animal studies tofacitinib conducted prior human trials showed carcinogenesis mutagenesis impairment commonly reported adverse reactions first three months controlled clinical trials occurring patients treated tofacitinib citrate monotherapy combination dmards upper respiratory tract infections headache diarrhea nasopharyngitis common tofacitinib required fda boxed warning label possible injury death due problems infections lymphoma malignancies arise use serious infections leading hospitalization death including tuberculosis bacterial invasive fungal viral opportunistic infections occurred patients receiving tofacitinib epstein barr virusassociated posttransplant lymphoproliferative disorder observed increased rate renal transplant patients treated tofacitinib immunosuppressive medications patients warned avoid use tofacitinib citrate active serious infection including localized infections doctors advised use caution patients may increased risk gastrointestinal perforations laboratory monitoring recommended due potential changes lymphocytes neutrophils hemoglobin liver enzymes lipids tofacitinib claims contraindications doctors advised reduce patients dosage combined potent inhibitors cytochrome ketoconazole one combined medications result moderate inhibition potent inhibition fluconazole furthermore immunizations live vaccines avoided tofacitinib according postmarketing research tofacitinib may also increase risk pulmonary embolism prescribers consider risk factors pulmonary embolism including age obesity smoking immobilization prescribing medication patients taking medication irrespective indication risk factors monitored signs symptoms pulmonary inhibitor enzyme janus kinase janus kinase jak means interferes jakstat signaling pathway transmits extracellular information cell nucleus influencing dna mouse model established arthritis tofacitinib rapidly improved disease inhibiting production inflammatory mediators suppressing genes joint tissue efficacy disease model correlated inhibition signaling pathways suggesting tofacitinib may exert therapeutic benefit via pathways exclusive inhibition potential significance inhibition first discovered laboratory john oshea immunologist national institute arthritis musculoskeletal skin diseases national institutes health pfizer approached nih form publicprivate partnership evaluate bring market experimental compounds based pfizer initially declined partnership agreed elimination nih policy dictating market price product resulting partnership would need commensurate investment public taxpayer revenue health safety needs pfizer worked osheas laboratory define structure function receptors handled drug discovery preclinical development clinical development tofacitinib drug coded development original recommended international nonproprietary name rinn overruled inn approval process optimally differentiable existing inns name tofacitinib proposed became inn november fda approved tofacitinib treatment rheumatoid study showed tofacitinib treatment able convert white fat tissues metabolically active brown fat suggesting may potential applications treatment november fda approved tofacitinib treat adults moderately severely active rheumatoid arthritis inadequate response intolerant fda approved fivemg twicedaily dose grounds higher dose considered adequate risktobenefit september fda approved tofacitinib treatment children adolescents two years age older active polyarticular course juvenile idiopathic december fda approved tofacitinib treatment adults active ankylosing june tofacitinib available generic medicine tofacitinib marketed xeljanz except russia marketed demonstrated effectiveness treatment psoriasis phase iii studies november studied immunological diseases well prevention organ transplant tofacitinib investigational drug psoriasis october demonstrated effectiveness plaque psoriasis phase iii randomized controlled trials comparison placebo particular tenmg twicedaily dose tofacitinib shown inferior etanercept mg subcutaneously twice october fda rejected approval tofacitinib treatment psoriasis due safety based preclinical studies mouse model tofacitinib investigated treatment alopecia areata early case suggested potential efficacy phase ii openlabel clinical published tandem phase ii clinical trial showing june case report woman vitiligo showed noticeable improvement taking tofacitinib five results using tofacitinib six patients recalcitrant atopic dermatitis published september saw improvement atopic dermatitis without adverse results phase iii randomised doubleblind placebocontrolled trial reported showed significant improvements patients active ankylosing spondylitis compared november studied treatment inflammatory bowel fda approved tofacitinib may treatment ulcerative httpsenwikipediaorgwikitofacitinib